Bone Biologics (BBLG) Other financing activities (2013 - 2024)
Bone Biologics (BBLG) posted quarterly Other financing activities of $287233.0 for Q3 2024, down 77.02% quarter-over-quarter from $1.2 million in Q1 2016.
Powered by 
Analysis
Bone Biologics (BBLG) Other financing activities (2013 - 2024) Analysis & Trends
Bone Biologics (BBLG) has reported Other financing activities for 3 consecutive years, with $287233.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Other financing activities changed N/A year-over-year to $287233.0; the TTM figure through Dec 2024 stood at $287233.0 (changed N/A YoY), while the FY2024 annual figure was $662.0, changed N/A from the prior year.
- Other financing activities retreated to $287233.0 in Q3 2024 per BBLG's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other financing activities topped out at $287233.0 in Q3 2024 and bottomed at $287233.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 287,233.00 |
| Mar 31, 2016 | 1.25 Mn |
| Jul 31, 2013 | 4,994.00 |